Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) insider Jacques Dumas sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the transaction, the insider now owns 17,500 shares in the company, valued at approximately $105,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jacques Dumas also recently made the following trade(s):

  • On Thursday, August 17th, Jacques Dumas sold 7,155 shares of Tetraphase Pharmaceuticals stock. The stock was sold at an average price of $5.86, for a total value of $41,928.30.

Tetraphase Pharmaceuticals, Inc. (TTPH) opened at 6.51 on Friday. The stock’s 50 day moving average price is $6.56 and its 200-day moving average price is $7.09. Tetraphase Pharmaceuticals, Inc. has a 52 week low of $3.11 and a 52 week high of $9.93. The company’s market cap is $332.36 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The company had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter in the prior year, the firm posted ($0.47) earnings per share. The business’s revenue was up 28.2% on a year-over-year basis. On average, equities research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post ($2.55) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/27/insider-selling-tetraphase-pharmaceuticals-inc-ttph-insider-sells-105000-00-in-stock.html.

Several hedge funds have recently bought and sold shares of the company. Wade G W & Inc. acquired a new stake in Tetraphase Pharmaceuticals during the first quarter worth $138,000. Teza Capital Management LLC boosted its position in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares in the last quarter. Citadel Advisors LLC boosted its position in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares in the last quarter. UBS Group AG boosted its position in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares in the last quarter. Finally, AXA purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth approximately $132,000. Hedge funds and other institutional investors own 35.93% of the company’s stock.

A number of equities analysts have recently weighed in on TTPH shares. BMO Capital Markets reiterated a “buy” rating and set a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research note on Wednesday, August 9th. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $8.00 to $15.00 in a research note on Wednesday, July 26th. HC Wainwright started coverage on Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price on the stock. Finally, BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $10.65.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.